NASDAQ:BGLC BioNexus Gene Lab Q2 2026 Earnings Report $1.34 +0.12 (+9.84%) As of 11:49 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast BioNexus Gene Lab EPS ResultsActual EPS-$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABioNexus Gene Lab Revenue ResultsActual Revenue$0.08 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioNexus Gene Lab Announcement DetailsQuarterQ2 2026Date8/14/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile BioNexus Gene Lab Earnings HeadlinesBioNexus Gene Lab Corp. (NASDAQ:BGLC) Shares Shorted: Short Interest Up 74.0% in SeptemberSeptember 30 at 3:01 AM | americanbankingnews.comBioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working VisitJuly 28, 2026 | globenewswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 1 at 1:00 AM | Base Camp Trading (Ad)BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-DevelopmentMay 29, 2026 | globenewswire.comBioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard ...March 11, 2026 | markets.businessinsider.comBioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion DiagnosticsMarch 11, 2026 | quiverquant.comQSee More BioNexus Gene Lab Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioNexus Gene Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNexus Gene Lab and other key companies, straight to your email. Email Address About BioNexus Gene LabBioNexus Gene Lab (NASDAQ:BGLC) (NASDAQ:BGLC) is a biotechnology and molecular diagnostics company focused on developing genetic tests intended to support the early detection of cancer and other diseases. Its diagnostic work uses blood-based and molecular analysis to identify biological indicators that may help healthcare providers assess disease risk and guide further evaluation. The company operates through two primary business areas: Molecular Diagnostics and Chemical Trading. The Molecular Diagnostics segment develops and commercializes genetic testing products, while the Chemical Trading segment distributes industrial chemicals and related products to customers in its served markets. BioNexus Gene Lab is headquartered in Kuala Lumpur, Malaysia, and its operations have included activities in the Malaysian market. The company was established in 2017 and has pursued a business model that combines biotechnology and diagnostic development with chemical distribution.View BioNexus Gene Lab ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
